Because the drug doesn’t target the brain, it has less potential for addiction. Learn why this could help the opioid crisis.

Six-year-old Hassan Abed Raboh lives with an excruciating bladder condition that 25 operations at Gaza hospitals could not ...

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for ...

Patients seeking an opioid-free way to handle pain experienced in the short-term will soon have a new option.

Suzetrigine, to be sold under the brand name Journavx, is the first new type of pain medicine approved by the FDA in more ...

The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...

Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but ...

The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...

The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...

A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.